Mesa Laboratories, Inc. (MLAB)

Mesa Laboratories' stock price has been impacted by several events in the past six months. The CEO transition on March 9, 2026, led to a significant stock decline. Quarterly dividends were declared on April 2, 2026, and January 7, 2026. Third-quarter results were announced on February 3, 2026, reporting a 3.6% revenue increase. The share price experienced a 35.85% decline between March 24, 2025, and March 23, 2026.

Explicit statements detailing overall demand seasonality for Mesa Laboratories' diverse product portfolio are not readily available. However, the company's third fiscal quarter report indicated a revenue decline in its Calibration Solutions segment due to a non-repeating end of calendar year order acceleration in the previous year related to its renal care product lines. The company's overall revenue for the quarter ending December 31, 2025, was $65.13 million, showing a 3.64% growth year-over-year.

Mesa Laboratories, Inc. is a global leader in life science tools and quality control solutions, operating in the Scientific & Technical Instruments industry and serving regulated markets like pharmaceutical, healthcare, and medical device industries. The company operates through four divisions: Sterilization and Disinfection Control (SDC), Clinical Genomics (CG), Biopharmaceutical Development (BPD), and Calibration Solutions (CS).

Mesa Laboratories has a global presence with operations in North America, Europe, and the Asia Pacific region. Manufacturing occurs in the United States and Europe, with products marketed by its sales personnel in the U.S., Canada, Europe, and Japan, and through distributors worldwide.

Mesa Laboratories emphasizes its commitment to quality and safety, holding certifications such as ISO/IEC 13485:2016 and ISO/IEC 17025:2017. While older employee reviews mentioned workplace challenges, no specific events impacting the company's brand reputation in the past year were found.

Mesa Laboratories has a diverse ownership structure, predominantly held by institutional investors. As of April 8, 2026, there were 217 institutional owners holding 4,748,235 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Long Path Partners LP. The largest individual shareholder is Evan Guillemin, owning 3.63% of the company.